Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Lohmann

Physician Assistant, Surgical Woodbridge, VA Physician Assistant

NPI 1417275629 CMS profile 11074641

15941 Donald Curtis Dr Ste 200, Woodbridge, VA 22191

Open in the dashboard

General payments

$88,120

455 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Lohmann of Woodbridge, VA is reported in the CMS Open Payments database as having received $88,120 across 455 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,199 150
2024 General $24,719 102
2023 General $11,323 78
2022 General $11,972 77
2021 General $8,907 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Lohmann
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Kelly Lohmann were reported at $31,199. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Kelly Lohmann Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $8,907 $111 $36–$285 $132
2022 $11,972 $126 $44–$350 $149
2023 $11,323 $137 $47–$355 $160
2024 $24,719 $146 $49–$384 $164
2025 $31,199 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $43,500 179 payments
  2. Alkermes, Inc. $38,350 110 payments
  3. Allergan Inc. $1,837 2 payments
  4. ITI, Inc. $1,045 34 payments
  5. Otsuka America Pharmaceutical, Inc. $639 32 payments
  6. Teva Pharmaceuticals USA, Inc. $538 16 payments
  7. Janssen Pharmaceuticals, Inc $474 15 payments
  8. Vanda Pharmaceuticals Inc. $469 14 payments
  9. Neurocrine Biosciences, Inc. $463 17 payments
  10. Lundbeck LLC $235 13 payments
  11. Other $571 23 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $70,525 46 payments
  2. Food and Beverage $8,100 357 payments
  3. Travel and Lodging $5,376 45 payments
  4. Consulting Fee $3,820 1 payment
  5. Education $298 6 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $39,085 144 payments
  2. LYBALVI Cns $38,273 106 payments
  3. LYBALVI Cns $37,327 76 payments
  4. LYBALVI Cns $37,231 71 payments
  5. LYBALVI Cns $37,231 71 payments
  6. VRAYLAR Neuroscience $4,724 35 payments
  7. ARISTADA Cns $1,119 39 payments
  8. ARISTADA Cns $1,119 39 payments
  9. ARISTADA Cns $1,023 34 payments
  10. ARISTADA Cns $1,023 34 payments
  11. Other $4,934 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

3,697

Median for Physician Assistant: 241

Drug cost

$1,148,643

Median for Physician Assistant: $4,110

Branded share of claims

16.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Trinza Paliperidone Palmitate Brand 24 $216,742
Aristada Aripiprazole Lauroxil Brand 60 $184,057
Invega Sustenna Paliperidone Palmitate Brand 45 $145,634
Abilify Maintena Aripiprazole Brand 43 $122,450
Lybalvi Olanzapine/Samidorphan Malate Brand 63 $100,117
Vraylar Cariprazine Hcl Brand 53 $87,745
Rexulti Brexpiprazole Brand 47 $74,177
Risperdal Consta Risperidone Microspheres Brand 26 $39,301
Aripiprazole Generic 276 $33,759
Caplyta Lumateperone Tosylate Brand 15 $26,804

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$19,729

Medicare's payments for the services billed

Medicare patients

81

Average age 51

Services billed

370

47 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 48%
Diabetes 26%
Depression 21%
Arthritis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYBALVI
  • Alkermes, Inc. $14,254
$14,254 63 —
VRAYLAR
  • AbbVie, Inc. $9,272
$9,272 53 —
ARISTADA
  • Alkermes, Inc. $305
$305 60 —
FANAPT
  • Vanda Pharmaceuticals Inc. $195
$195 12 —
ABILIFY ASIMTUFII
  • Lundbeck LLC $74
  • Otsuka America Pharmaceutical, Inc. $28
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

455 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record